Abstract 1868P
Background
Patients with incurable cancer often face difficult decisions about their care. Shared decision making (SDM) can help people make the decisions that are right for them, by supporting understanding and ensuring their priorities are considered. Essential for this is health literacy (HL) - the personal competencies and situational resources needed for people to process information to make decisions. This study sought to understand the barriers to SDM in the context of HL from the perspective of patients and clinicians, and consider how they may be overcome.
Methods
This mixed methods study comprised: 1) semi-structured interviews with patients with incurable cancer and suspected HL difficulties, identified by clinicians from 2 district hospitals; and 2) an online survey of NHS healthcare professionals caring for patients with incurable cancer. Interview data were analysed using the Framework Approach to identify important and recurrent themes. For the survey, a descriptive analysis was carried out for the quantitative data, and thematic analysis for the qualitative data.
Results
Twenty-one interviews were conducted. Patients had a range of diagnoses and had received various treatments. Themes related to experiences (supportive staff in an imperfect system, additional pressure from COVID-19, in the expert’s hands, treatment not so bad) and barriers to SDM (emotional hurdles, accessing and understanding information, wanting to be a good patient). Survey participants (N=70) included doctors, nurses, and a pharmacist. Views towards SDM ranged from those who aim to ‘always’ use it, to those who feel its use should be limited. Patient, clinician, and situational barriers were identified. Key challenges for SDM include the persistence of paternalistic clinician-patient roles, dealing with emotional hurdles, and practical issues.
Conclusions
There are socio-cultural, emotional and system barriers to SDM in incurable cancer for those with HL difficulties. Addressing this combination of issues will be important to fully embed its use in practice. Recommendations to improve SDM range from large scale policy changes to provision of easily accessible and understandable patient information and decision aids in a variety of formats.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Southampton.
Funding
Robert White Legacy Fund.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2008P - Brazilian real-world data of immunotherapy (IO) in extensive disease small cell lung cancer (ES-SCLC)
Presenter: Flávia Duarte
Session: Poster session 05
2009P - CNS efficacy of immune checkpoint inhibitors when combined to stereotactic radiosurgery in extensive stage small cell lung cancer
Presenter: Muhammad Awidi
Session: Poster session 05
2010P - Non-invasive radiomics signature predicts response to combination chemoimmunotherapy in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Stuthi Perimbeti
Session: Poster session 05
2011P - Machine-derived features of tumor infiltrating lymphocytes (TILs) as biomarkers of clinical outcomes to platinum chemotherapy in small cell lung cancer (SCLC)
Presenter: Prantesh Jain
Session: Poster session 05
2012P - Spatially resolved transcriptomics deciphers inter- and intra-tumor heterogeneity of small cell lung cancer
Presenter: xujie Sun
Session: Poster session 05
2013P - Investigating the clinical relevance of immune checkpoint expression in the peripheral blood of patients with small cell lung cancer (SCLC)
Presenter: Dimitrios Mavroudis
Session: Poster session 05
2014P - ATR inhibition upregulates PD-L1 and potentiates the antitumor immune response to chemoimmunotherapy in small cell lung cancer
Presenter: Triparna Sen
Session: Poster session 05
2015P - Association between gene characteristics and mutation abundance with the prognosis of small cell lung cancer
Presenter: Lian Yu
Session: Poster session 05
2016P - The role of galectin-1 in SCLC: Prognostic significance and therapeutic implications
Presenter: Arancha Cebrian
Session: Poster session 05
2017P - Comprehensive molecular profiling of small cell lung cancer patients treated with chemo-immunotherapy or chemotherapy alone
Presenter: Milena Urbini
Session: Poster session 05